Canonical Question
Phaemacopeia – Anticoagulants
Variant family: at least one exam appearance has different scope. The appearance record controls whether this master answer is safe to display on that Past Paper.
Master answer
Resource-backed answer.
Heparin - UFH vs LMWH · Phaemacopeia - Anticoagulants
The final migration will resolve this to the canonical TablePress/Pharmacopeia source instead of copying the table into this answer.
Exam appearances
| Exam | Exact wording | Relationship | Success |
|---|---|---|---|
| 2009B Q20 | Compare and contrast the pharmacology of heparin and enoxaparin. | historical_member | — |
| 2017B Q05 | Compare and contrast unfractionated heparin with low molecular weight heparin | historical_member | — |
| 2024A Q20 | Outline the important similarities and differences between unfractionated heparin and enoxaparin using the following headings (20% of marks each): (i) Mechanism of action (ii) Pharmacokinetics (iii) Adverse effects (iv) Dosing (v) Monitoring and reversal | historical_member | — |
| 2018B Q20 | Describe the pharmacology of heparin highlighting important differences between unfractionated and fractionated (low molecular weight) heparin. | historical_member | — |
| 2025B Q20 | Describe the following pharmacology of both unfractionated heparin and bivalirudin: (a) indications for use (10% of marks) (b) mechanism of action (30% of marks) (c) monitoring and reversal (10% of marks) (d) important pharmacokinetic differences and considerations when using in the intensive care unit (ICU) (30% of marks) (e) adverse effects (20% of marks). | variant | 35.00% |